Driehaus Capital PGEN Position
ActiveDriehaus Capital increased their position in Precigen Inc. (PGEN) in Q4 2025, holding $15.1M worth of shares across 3,601,674 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds PGEN.
There is an upcoming Phase 2 readout for PRGN-2009 plus Pembrolizumab in 654 days (Jan 30, 2028), making the timing of Driehaus's position particularly relevant.
Short interest stands at 17.4% of float with 8.3 days to cover, indicating significant bearish positioning against Driehaus's long thesis.
About Precigen Inc.
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Full company profile →Short Interest
17.4%
8.3 days to cover
Driehaus Capital PGEN Position History
Frequently Asked Questions
Does Driehaus Capital own PGEN?
Yes. As of Q4 2025, Driehaus Capital holds 3,601,674 shares of Precigen Inc. (PGEN) valued at $15.1M. This data comes from their SEC 13F filing.
How many hedge funds own PGEN?
2 specialist biotech hedge funds currently hold PGEN, including Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy PGEN?
Driehaus Capital's position in PGEN was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's PGEN position increasing or decreasing?
Driehaus Capital increased their PGEN position in the most recent quarter, adding 1,559,164 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PGENCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →